Nanogen exits array business
This article was originally published in The Gray Sheet
Executive Summary
Nanogen plans to close its array business and cut 20% of its staff to save about $15 million. The company originally announced it was considering dropping the business in September (1"The Gray Sheet" Sept. 24, 2007, p. 14). "Our analysis of alternatives for the array business has not resulted in any financially meaningful opportunities," COO David Ludvigson said Nov. 12. "The best way to meet our commitment to improving financial performance for our shareholders is to focus on our real-time PCR and point-of-care testing businesses." The restructuring will cost $6.9 million, charged to the third quarter, for inventory and assets related to the array business and $2.5 million in severance costs charged to the fourth quarter. The company will continue to supply most cartridges for the NanoChip electronic microarray system to customers through 2008
You may also be interested in...
Diagnostics In Brief
First genetic test for warfarin sensitivity cleared: Nanosphere's Verigene multiplex nucleic acid test for genetic variations that influence metabolism of the common blood-thinner warfarin is 510(k)-cleared Sept. 17. FDA updated the labeling of warfarin in August to explain that patients with variations in the CYP2C9 and VKORC1 genes may respond differently to the drug (1"The Gray Sheet" Aug. 20, 2007, p. 9). Other firms developing warfarin test kits include AutoGenomics, Nanogen, Third Wave Technologies and Luminex
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.